logo
#

Latest news with #BTIG12thAnnualMedTech

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Yahoo

time05-02-2025

  • Business
  • Yahoo

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ('Adaptive Biotechnologies') (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UTParticipating on Wednesday, February 12, 2025 TD Cowen 45th Annual Health Care Conference in Boston, MAFireside chat on Monday, March 3, 2025, at 11:10 a.m. Eastern Time Interested parties may access live and archived webcasts of the session on the 'Investors' section of the company website at: About Adaptive Biotechnologies Adaptive Biotechnologies ('we' or 'our') is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations and FP&A201-396-1687investors@ ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director206-279-2423media@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store